Free Trial
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel Free CRTX Stock Alerts

CRISM Therapeutics (CRTX) Competitors

GBX 11.50 -0.50 (-4.17%)
As of 09:55 AM Eastern
Compare

CRTX vs. GSP, CLA, CDL, GWMO, and CTL

Should you buy CRISM Therapeutics stock or one of its competitors? MarketBeat compares CRISM Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CRISM Therapeutics include Gensource Potash (GSP), Celsius Resources (CLA), Cloudbreak Discovery (CDL), Great Western Mining (GWMO), and CleanTech Lithium (CTL). These companies are all part of the "other industrial metals & mining" industry.

How does CRISM Therapeutics compare to Gensource Potash?

Gensource Potash (LON:GSP) and CRISM Therapeutics (LON:CRTX) are both small-cap basic materials companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, media sentiment, profitability and analyst recommendations.

Gensource Potash has a beta of 1, suggesting that its stock price has a similar volatility profile to the broader market.Comparatively, CRISM Therapeutics has a beta of 0.598, suggesting that its stock price is 40% less volatile than the broader market.

3.7% of CRISM Therapeutics shares are owned by institutional investors. 6.2% of Gensource Potash shares are owned by insiders. Comparatively, 77.3% of CRISM Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Gensource Potash's return on equity of -45.96% beat CRISM Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Gensource PotashN/A -45.96% -10.31%
CRISM Therapeutics N/A -78.00%-26.77%

In the previous week, Gensource Potash had 1 more articles in the media than CRISM Therapeutics. MarketBeat recorded 1 mentions for Gensource Potash and 0 mentions for CRISM Therapeutics. Gensource Potash's average media sentiment score of 0.64 beat CRISM Therapeutics' score of 0.00 indicating that Gensource Potash is being referred to more favorably in the media.

Company Overall Sentiment
Gensource Potash Positive
CRISM Therapeutics Neutral

CRISM Therapeutics has higher revenue and earnings than Gensource Potash. CRISM Therapeutics is trading at a lower price-to-earnings ratio than Gensource Potash, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gensource PotashN/AN/A-£6.58M-£0.01N/A
CRISM Therapeutics£25K237.98-£792.20K-£4.40N/A

Summary

Gensource Potash beats CRISM Therapeutics on 6 of the 11 factors compared between the two stocks.

How does CRISM Therapeutics compare to Celsius Resources?

CRISM Therapeutics (LON:CRTX) and Celsius Resources (LON:CLA) are both small-cap basic materials companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation.

Celsius Resources' return on equity of -7.35% beat CRISM Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
CRISM TherapeuticsN/A -78.00% -26.77%
Celsius Resources N/A -7.35%-4.41%

In the previous week, CRISM Therapeutics' average media sentiment score of 0.00 beat Celsius Resources' score of -1.01 indicating that CRISM Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
CRISM Therapeutics Neutral
Celsius Resources Negative

CRISM Therapeutics has a beta of 0.598, indicating that its share price is 40% less volatile than the broader market. Comparatively, Celsius Resources has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market.

CRISM Therapeutics has higher revenue and earnings than Celsius Resources. Celsius Resources is trading at a lower price-to-earnings ratio than CRISM Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CRISM Therapeutics£25K237.98-£792.20K-£4.40N/A
Celsius Resources£647.0024,145.85-£2.33M-£0.06N/A

3.7% of CRISM Therapeutics shares are held by institutional investors. Comparatively, 0.0% of Celsius Resources shares are held by institutional investors. 77.3% of CRISM Therapeutics shares are held by company insiders. Comparatively, 21.5% of Celsius Resources shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

CRISM Therapeutics beats Celsius Resources on 6 of the 11 factors compared between the two stocks.

How does CRISM Therapeutics compare to Cloudbreak Discovery?

Cloudbreak Discovery (LON:CDL) and CRISM Therapeutics (LON:CRTX) are both small-cap basic materials companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk.

CRISM Therapeutics has higher revenue and earnings than Cloudbreak Discovery. Cloudbreak Discovery is trading at a lower price-to-earnings ratio than CRISM Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cloudbreak DiscoveryN/AN/A-£2.87M-£0.14N/A
CRISM Therapeutics£25K237.98-£792.20K-£4.40N/A

0.4% of Cloudbreak Discovery shares are owned by institutional investors. Comparatively, 3.7% of CRISM Therapeutics shares are owned by institutional investors. 41.2% of Cloudbreak Discovery shares are owned by company insiders. Comparatively, 77.3% of CRISM Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Cloudbreak Discovery's average media sentiment score of 0.00 equaled CRISM Therapeutics'average media sentiment score.

Company Overall Sentiment
Cloudbreak Discovery Neutral
CRISM Therapeutics Neutral

CRISM Therapeutics has a net margin of 0.00% compared to Cloudbreak Discovery's net margin of -842.88%. Cloudbreak Discovery's return on equity of 576.19% beat CRISM Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Cloudbreak Discovery-842.88% 576.19% -31.77%
CRISM Therapeutics N/A -78.00%-26.77%

Cloudbreak Discovery has a beta of 1.372, indicating that its share price is 37% more volatile than the broader market. Comparatively, CRISM Therapeutics has a beta of 0.598, indicating that its share price is 40% less volatile than the broader market.

Summary

CRISM Therapeutics beats Cloudbreak Discovery on 7 of the 10 factors compared between the two stocks.

How does CRISM Therapeutics compare to Great Western Mining?

Great Western Mining (LON:GWMO) and CRISM Therapeutics (LON:CRTX) are both small-cap basic materials companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.

Great Western Mining has higher earnings, but lower revenue than CRISM Therapeutics. CRISM Therapeutics is trading at a lower price-to-earnings ratio than Great Western Mining, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Great Western MiningN/AN/AN/A-£2.85N/A
CRISM Therapeutics£25K237.98-£792.20K-£4.40N/A

5.8% of Great Western Mining shares are held by institutional investors. Comparatively, 3.7% of CRISM Therapeutics shares are held by institutional investors. 6.6% of Great Western Mining shares are held by company insiders. Comparatively, 77.3% of CRISM Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Great Western Mining had 2 more articles in the media than CRISM Therapeutics. MarketBeat recorded 2 mentions for Great Western Mining and 0 mentions for CRISM Therapeutics. Great Western Mining's average media sentiment score of 1.30 beat CRISM Therapeutics' score of 0.00 indicating that Great Western Mining is being referred to more favorably in the media.

Company Overall Sentiment
Great Western Mining Positive
CRISM Therapeutics Neutral

Great Western Mining's return on equity of -9.48% beat CRISM Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Great Western MiningN/A -9.48% -5.92%
CRISM Therapeutics N/A -78.00%-26.77%

Great Western Mining has a beta of 0.19, meaning that its stock price is 81% less volatile than the broader market. Comparatively, CRISM Therapeutics has a beta of 0.598, meaning that its stock price is 40% less volatile than the broader market.

Summary

Great Western Mining beats CRISM Therapeutics on 7 of the 10 factors compared between the two stocks.

How does CRISM Therapeutics compare to CleanTech Lithium?

CleanTech Lithium (LON:CTL) and CRISM Therapeutics (LON:CRTX) are both small-cap basic materials companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

In the previous week, CleanTech Lithium had 1 more articles in the media than CRISM Therapeutics. MarketBeat recorded 1 mentions for CleanTech Lithium and 0 mentions for CRISM Therapeutics. CleanTech Lithium's average media sentiment score of 0.67 beat CRISM Therapeutics' score of 0.00 indicating that CleanTech Lithium is being referred to more favorably in the media.

Company Overall Sentiment
CleanTech Lithium Positive
CRISM Therapeutics Neutral

CleanTech Lithium's return on equity of -43.43% beat CRISM Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
CleanTech LithiumN/A -43.43% -13.50%
CRISM Therapeutics N/A -78.00%-26.77%

CRISM Therapeutics has higher revenue and earnings than CleanTech Lithium. CRISM Therapeutics is trading at a lower price-to-earnings ratio than CleanTech Lithium, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CleanTech LithiumN/AN/A-£2.19M£0.948.16
CRISM Therapeutics£25K237.98-£792.20K-£4.40N/A

CleanTech Lithium currently has a consensus target price of GBX 20, indicating a potential upside of 160.59%. Given CleanTech Lithium's stronger consensus rating and higher possible upside, equities research analysts plainly believe CleanTech Lithium is more favorable than CRISM Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CleanTech Lithium
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
CRISM Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

0.1% of CleanTech Lithium shares are held by institutional investors. Comparatively, 3.7% of CRISM Therapeutics shares are held by institutional investors. 5.5% of CleanTech Lithium shares are held by insiders. Comparatively, 77.3% of CRISM Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

CleanTech Lithium has a beta of -0.79, suggesting that its stock price is 179% less volatile than the broader market. Comparatively, CRISM Therapeutics has a beta of 0.598, suggesting that its stock price is 40% less volatile than the broader market.

Summary

CleanTech Lithium beats CRISM Therapeutics on 9 of the 14 factors compared between the two stocks.

Get CRISM Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRTX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CRTX vs. The Competition

Export
MetricCRISM TherapeuticsOther Industrial Metals & Mining IndustryMaterials SectorLON Exchange
Market Cap£5.95M£1.58B£4.80B£2.74B
Dividend YieldN/A6.55%4.97%6.07%
P/E Ratio-2.6130.8923.12365.80
Price / Sales237.9856,691.356,725.2688,011.55
Price / CashN/A24.6327.6927.89
Price / Book0.275.646.887.66
Net Income-£792.20K£70.60M£159.01M£5.89B
7 Day PerformanceN/A0.37%-0.57%0.17%
1 Month Performance-8.00%4.22%1.10%1.87%
1 Year Performance-44.98%131.90%82.36%86.36%

CRISM Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CRTX
CRISM Therapeutics
N/AGBX 11.50
-4.2%		N/A-45.3%£5.95M£25KN/A4
GSP
Gensource Potash
N/AN/AN/AN/A£23.61MN/AN/AN/A
CLA
Celsius Resources
N/AGBX 0.50
+8.7%		N/A+46.2%£18.60M£647.00N/AN/A
CDL
Cloudbreak Discovery
N/AGBX 0.76
+16.9%		N/A+233.3%£16.84MN/AN/A4
GWMO
Great Western Mining
N/AGBX 3.97
+4.5%		N/A+184.0%£16.48MN/AN/A9

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:CRTX) was last updated on 5/15/2026 by MarketBeat.com Staff.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Why this tiny stock may move before the SpaceX IPO drops
The projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...
Behind the Markets | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel